Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Recurrence, Local
IRC-determined results were highly consistent with those determined by investigators, demonstrating that bevacizumab plus GC provides a significant improvement in PFS and ORR. These results suggest that investigators can reliably assess disease progression and objective response in recurrent ovarian cancer using RECIST, without the necessity of a full IRC review.